Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Walnut Capital | Hong Kong | Financial | Investment Banking & Investment Services | 155.9% | HKD 850.91M | 1,952.9x | 22.61 | HKD 0.89 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | 153.8% | HKD 3.12B | -18.2x | -0.33 | HKD 3.73 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -48.2% Downside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | 145.4% | HKD 24.51B | -15.1x | -1.5 | HKD 37.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.3% Downside | Upgrade to Pro+ | |
China Investment and Finance | Hong Kong | Financial | Investment Banking & Investment Services | 128.6% | HKD 536.38M | -34.8x | -0.49 | HKD 1.31 | -18.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fengyinhe Holdings | Hong Kong | Financial | Investment Banking & Investment Services | 117.9% | HKD 1.03B | 11.3x | -3.04 | HKD 3.08 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | 96.3% | HKD 7.06B | 43.3x | 0.22 | HKD 6.40 | -12.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -34.7% Downside | Upgrade to Pro+ | |
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | 63% | HKD 1.81B | -13.9x | -0.34 | HKD 0.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | 61.4% | HKD 4.89B | 166.6x | 1.52 | HKD 7.30 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
Lepu Scientech Medical Technology | Hong Kong | Healthcare | Healthcare Equipment & Supplies | 58.1% | HKD 7.68B | -17.7x | 0.04 | HKD 20.10 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -74.8% Downside | Upgrade to Pro+ | |
Giant Biogene Holding | Hong Kong | Consumer Non-Cyclicals | Personal & Household Products & Services | 39.8% | HKD 85.33B | 36.4x | 0.98 | HKD 78.05 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.9% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | 31.9% | HKD 16.27B | -30.1x | -0.63 | HKD 45.15 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.9% Upside | Upgrade to Pro+ | |
Horizon Robotics | Hong Kong | Consumer Cyclicals | Automobiles & Auto Parts | 25.7% | HKD 91.08B | -28.6x | 0.39 | HKD 7.20 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | 16.7% | HKD 2.62B | -7x | -0.38 | HKD 5.92 | -8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures Co | Hong Kong | Financial | Investment Banking & Investment Services | 6% | HKD 7.98B | 50.8x | 0.34 | HKD 3.25 | 14.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | 5.1% | HKD 194.80B | -63.7x | -1.25 | HKD 127.80 | -9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.9% Upside | Upgrade to Pro+ | |
Tong Tong AI Social | Hong Kong | Financial | Banking Services | 3.4% | HKD 1.59B | 24.4x | -1.32 | HKD 0.31 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Emperor Capital | Hong Kong | Financial | Banking Services | -1.6% | HKD 424.67M | 6.2x | 0.04 | HKD 0.06 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Merchants China Direct | Hong Kong | Financial | Investment Banking & Investment Services | -7.6% | HKD 2.08B | 2.2x | 0 | HKD 13.68 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Guolian Securities Co | Hong Kong | Financial | Investment Banking & Investment Services | -9.9% | HKD 56.95B | 11.2x | 0.22 | HKD 3.77 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.8% Upside | Upgrade to Pro+ | |
ARTA TechFin | Hong Kong | Financial | Investment Banking & Investment Services | -15.8% | HKD 691.90M | -17.4x | -0.28 | HKD 0.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CMBC Capital | Hong Kong | Financial | Investment Banking & Investment Services | -32.1% | HKD 321.12M | 5.7x | 0.06 | HKD 0.30 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |